NKGen Biotech, a clinical-stage biotechnology company developing innovative natural killer (NK) cell therapeutics, announced that CEO Dr. Paul Y. Song will present clinical findings for troculeucel, the company's investigational autologous enhanced NK cell therapy for Alzheimer's disease, at two major international conferences in Asia.
World Congress of Neurology Presentation
Dr. Song will present at the XXVII World Congress of Neurology (WCN 2025) taking place in Seoul, South Korea, October 12-15, 2025. The presentation, titled "Expanded Non-genetically Modified Natural Killer Cells (Troculeucel) with Enhanced Cytotoxicity in Moderate/Advanced Alzheimer's Disease. Scientific Rationale with Preliminary Clinical and Biomarker Results," is scheduled for October 15, 2025, at 11:50 AM Korean Standard Time in Conference Room North 201.
WCN 2025 serves as a premier global forum that brings together leading neurologists, researchers, and healthcare professionals to exchange knowledge, foster collaboration, and explore breakthrough innovations in neurological science. The presentation reflects NKGen's continued commitment to advancing neurological care and contributing to the future of Alzheimer's treatment.
China Great Bay Forum Presentation
Additionally, Dr. Song will discuss the scientific rationale and recent clinical data supporting troculeucel's use in neurodegenerative diseases at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou, China, September 25-26, 2025. His presentation, "Use of Troculeucel (Autologous Enhanced Natural Killer Cell Therapy) for Neurodegenerative Diseases – Scientific Rationale and Latest Clinical Data," will take place on September 25, 2025, from 3:20 PM to 3:45 PM China Standard Time.
The forum, hosted in Guangzhou Knowledge City, draws over 1,200 experts and features more than 90 speakers. It serves as a dynamic platform to foster innovation and collaboration across cell and gene therapy, RNA therapeutics, and stem cell research, uniting leading voices from biotech startups to global pharmaceutical leaders.
About Troculeucel
Troculeucel represents a novel cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. The therapy has achieved a significant regulatory milestone with the World Health Organization's assignment of troculeucel as the International Nonproprietary Name (INN) for SNK01. This WHO INN approval establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.
The company plans to make copies of both presentations available on its website under the Scientific Publications section once the events conclude. Previously disclosed scientific data on troculeucel for neurodegenerative disease can also be accessed on the same page, with the latest updates on clinical trials and regulatory announcements available on the company's News page.
